We hope Beyfortus will be shipping soon and we will have some in office before RSV season begins 11/1. Here is the update we got from the manufacturer.
Dear Healthcare Professional,
I am pleased to share that the US Food and Drug Administration (FDA) recently approved a new manufacturing line for Beyfortus® (nirsevimab-alip) 50 mg and 100 mg Injection. This accomplishment, aimed at equitable access, was made possible through close partnership with the White House, Centers for Disease Control and Prevention, the US Food and Drug Administration, and healthcare providers to make Beyfortus widely available. This marks a critical milestone toward helping to protect infants from respiratory syncytial virus (RSV) disease and means you will be well-equipped to start immunizing right at the beginning of the RSV season.
Our goal is clear: to ensure an ample supply of Beyfortus doses is available to immunize every eligible patient in the US for the 2024/2025 RSV season. This includes babies born before or during their first RSV season and certain infants up to 24 months old who remain vulnerable to severe RSV disease through their second RSV season.1 We will continue to build upon our supply capacity to ensure ample doses for future seasons to come.
Shipping is already underway at our other facilities, and our newly approved site will ship doses soon. With the addition of this new manufacturing line, we expect a vast majority of Beyfortus doses to be available by October for private healthcare providers and the Centers for Disease Control and Prevention for its Vaccines for Children (VFC) Program. This hopes to ensure equitable access across all channels ahead of RSV season.